CLINICAL_TRIALS
trial_result
· 2023-07-27
Clinical Trial Update: EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) [Phase 3]
Summary
The EMPA-KIDNEY Phase 3 trial evaluating empagliflozin for heart and kidney protection in chronic kidney disease has completed with results posted in July 2023.…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-07-27